Axsome Therapeutics
AXSM
179 hedge funds and large institutions have $1.95B invested in Axsome Therapeutics in 2020 Q4 according to their latest regulatory filings, with 22 funds opening new positions, 66 increasing their positions, 59 reducing their positions, and 17 closing their positions.
29% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 17
12% more repeat investments, than reductions
Existing positions increased: 66 | Existing positions reduced: 59
3% more funds holding
Funds holding: 174 → 179 (+5)
0.29% less ownership
Funds ownership: 64.51% → 64.22% (-0.29%)
2% less capital inflows, than outflows
Capital inflows: $148M | Capital outflows: $151M
10% less call options, than puts
Call options by funds: $49.9M | Put options by funds: $55.3M
20% less funds holding in top 10
Funds holding in top 10: 5 → 4 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$36.8M |
| 2 |
HHLR Advisors
Grand Cayman,
Cayman Islands
|
+$26.9M |
| 3 |
Iridian Asset Management
Westport,
Connecticut
|
+$25.5M |
| 4 |
Peregrine Capital Management
Minneapolis,
Minnesota
|
+$10.9M |
| 5 |
AllianceBernstein
Nashville,
Tennessee
|
+$4.15M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RA Capital Management
Boston,
Massachusetts
|
-$28.4M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$16.7M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
-$14.2M |
| 4 |
BBA
Baker Bros. Advisors
New York
|
-$13.5M |
| 5 |
Goldman Sachs
New York
|
-$11.4M |
AXSM Hedge Fund Activity: Q4 2020 in Review
179 of the 5,678 institutional investors tracked by Wall St. Rank reported a position in Axsome Therapeutics (AXSM) for Q4 2020, worth a combined $1.95B — up 14% from $1.71B a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new AXSM positions and 17 closed out — a net gain of 5 holders — while 66 added to existing stakes and 59 trimmed.
The largest buyer was Citadel Advisors, adding an estimated $36.8M. The largest seller was RA Capital Management, cutting an estimated $28.4M.
- 179 institutional investors held Axsome Therapeutics (AXSM) as of Q4 2020, up from 174 in Q3 2020.
- Funds reported $1.95B of Axsome Therapeutics stock for Q4 2020, up 14% quarter-over-quarter.
- 22 funds opened new Axsome Therapeutics positions in Q4 2020 and 17 closed out, a net change of +5 holders.
- The largest Axsome Therapeutics buyer in Q4 2020 was Citadel Advisors, an estimated $36.8M added.
- The largest Axsome Therapeutics seller in Q4 2020 was RA Capital Management, an estimated $28.4M sold.
Based on aggregated 13F filings for Q4 2020.